Autonomix Medical (NASDAQ:AMIX – Get Free Report) and Microbot Medical (NASDAQ:MBOT – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership.
Valuation & Earnings
This table compares Autonomix Medical and Microbot Medical”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Autonomix Medical | N/A | N/A | -$11.41 million | ($5.74) | -0.20 |
| Microbot Medical | N/A | N/A | -$11.44 million | ($0.58) | -5.03 |
Analyst Recommendations
This is a breakdown of current ratings for Autonomix Medical and Microbot Medical, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Autonomix Medical | 1 | 1 | 1 | 0 | 2.00 |
| Microbot Medical | 1 | 1 | 1 | 0 | 2.00 |
Autonomix Medical presently has a consensus price target of $5.00, indicating a potential upside of 342.48%. Microbot Medical has a consensus price target of $12.00, indicating a potential upside of 310.96%. Given Autonomix Medical’s higher probable upside, equities research analysts plainly believe Autonomix Medical is more favorable than Microbot Medical.
Risk & Volatility
Autonomix Medical has a beta of -2.8, meaning that its stock price is 380% less volatile than the S&P 500. Comparatively, Microbot Medical has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500.
Profitability
This table compares Autonomix Medical and Microbot Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Autonomix Medical | N/A | -172.93% | -133.39% |
| Microbot Medical | N/A | -76.27% | -67.54% |
Institutional and Insider Ownership
10.8% of Autonomix Medical shares are owned by institutional investors. Comparatively, 16.3% of Microbot Medical shares are owned by institutional investors. 6.2% of Autonomix Medical shares are owned by company insiders. Comparatively, 4.7% of Microbot Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Microbot Medical beats Autonomix Medical on 5 of the 9 factors compared between the two stocks.
About Autonomix Medical
Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.
About Microbot Medical
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
Receive News & Ratings for Autonomix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autonomix Medical and related companies with MarketBeat.com's FREE daily email newsletter.
